Barrett's oesophagus—cancer risk, biology and therapeutic management

Barrett's oesophagus is receiving increasing scrutiny as the rates of adenocarcinoma of the oesophagus rise. Because clinical features are not predictive of the presence of Barrett's oesophagus and most individuals with Barrett's oesophagus go undetected, a case can be made for surveillance endoscopy in patients with chronic reflux. Once Barrett's oesophagus is diagnosed patients should be entered into a surveillance programme despite lack of proof of efficacy. Scientific study of putative biological markers of increased risk has added dramatically to the understanding of the biology of the lesion, but currently the finding of high‐grade dysplasia remains the best marker predicting the presence of greatly increased risk of developing cancer. It is likely that newer molecular biology techniques will become clinically applicable biological markers in the future. Currently there is no effective medical nor surgical therapy to cause regression of the metaplastic Barrett's epithelium, however the application of novel de‐differentiating agents or ablation of the metaplastic epithelium while controlling oesophageal acid exposure and other environmental abnormalities offer hope that effective treatment of Barrett's oesophagus may someday be reality.

[1]  P. Blount,et al.  Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. , 1992, Gastroenterology.

[2]  R. Sampliner,et al.  Ornithine decarboxylase and polyamine levels in columnar upper gastrointestinal mucosae in patients with Barrett's esophagus. , 1988, Cancer research.

[3]  B. Reid,et al.  Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. , 1987, Gastroenterology.

[4]  J. Trent,et al.  Chromosomal rearrangements in Barrett's esophagus. A premalignant lesion of esophageal adenocarcinoma. , 1989, Cancer genetics and cytogenetics.

[5]  W G Doos,et al.  Adenocarcinoma and Barrett's esophagus. An overrated risk? , 1984, Gastroenterology.

[6]  P. Pairolero,et al.  Barrett's esophagus with high-grade dysplasia: an indication for esophagectomy? , 1992, The Annals of thoracic surgery.

[7]  McCallum Rw,et al.  Barrett's esophagus. Current assessment and future perspectives. , 1990 .

[8]  P. Blount,et al.  Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. , 1992, Gastroenterology.

[9]  E. Achkar,et al.  The cost of surveillance for adenocarcinoma complicating Barrett's esophagus. , 1988, The American journal of gastroenterology.

[10]  R. Sampliner,et al.  Esophageal ulceration associated with 13-cis-retinoic acid therapy in patients with Barrett's esophagus. , 1989, Gastrointestinal endoscopy.

[11]  R. Riddell.  Screening strategies in gastrointestinal cancer. , 1990, Scandinavian journal of gastroenterology. Supplement.

[12]  R. Sampliner,et al.  Ornithine decarboxylase activity in Barrett's esophagus: a potential marker for dysplasia. , 1988, Gastroenterology.

[13]  R. Sampliner,et al.  Management of high-grade dysplasia in Barrett's esophagus. , 1989, Journal of clinical gastroenterology.

[14]  M. Indelli,et al.  Barrett esophagus after chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF): an iatrogenic injury? , 1991, Annals of internal medicine.

[15]  C. Cooke,et al.  Barrett's esophagus: lack of association with adjuvant chemotherapy for localized breast carcinoma. , 1992, Gastrointestinal endoscopy.

[16]  A. Cameron,et al.  Barrett's esophagus: age, prevalence, and extent of columnar epithelium. , 1992, Gastroenterology.

[17]  T. Humphries.  Effects of long-term medical treatment with cimetidine and bethanechol in patients with esophagitis and Barrett's esophagus. , 1987, Journal of clinical gastroenterology.

[18]  J. G. van den Tweel,et al.  Barrett's esophagus: development of dysplasia and adenocarcinoma. , 1989, Gastroenterology.

[19]  H. Laks,et al.  Damus-Stansel-Kaye procedure: technical modifications. , 1992, The Annals of thoracic surgery.

[20]  M. Atkinson.  Barrett's oesophagus--to screen or not to screen? , 1989, Gut.

[21]  B. Reid,et al.  Progression to cancer in Barrett's esophagus is associated with genomic instability. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[22]  J. Jankowski.  Adenocarcinoma and Barrett's oesophagus. , 1992, Gut.

[23]  B. Dahms,et al.  Barrett's esophagus in children: a consequence of chronic gastroesophageal reflux. , 1984, Gastroenterology.

[24]  J. Roth,et al.  p53 gene mutations in Barrett's epithelium and esophageal cancer. , 1991, Cancer research.

[25]  N. Shepherd,et al.  Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy , 1993, Alimentary pharmacology & therapeutics.

[26]  R. McCallum,et al.  Barrett's esophagus. Current assessment and future perspectives. , 1990, Gastroenterology clinics of North America.

[27]  C. Winters,et al.  Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. , 1987, Gastroenterology.

[28]  D. Antonioli,et al.  Comparative features of esophageal and gastric adenocarcinomas: recent changes in type and frequency. , 1986, Human pathology.

[29]  M. Savary,et al.  Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas. , 1975, The Journal of thoracic and cardiovascular surgery.

[30]  D J Ballard,et al.  Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. , 1990, Gastroenterology.

[31]  B. Reid,et al.  Correlation of ultrastructural aberrations with dysplasia and flow cytometric abnormalities in Barrett's epithelium. , 1989, Gastroenterology.

[32]  S. Spechler.  Endoscopic surveillance for patients with Barrett esophagus: does the cancer risk justify the practice? , 1987, Annals of internal medicine.

[33]  J. Devière,et al.  Regression of Barrett's epithelium with omeprazole. , 1989, The New England journal of medicine.

[34]  A. Morelli,et al.  Effect of omeprazole on gastroesophageal reflux in Barrett's esophagus. , 1989, The American journal of gastroenterology.

[35]  R. Sampliner,et al.  Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus. , 1989, Gastroenterology.

[36]  B. Reid,et al.  Barrett's esophagus. Correlation between mucin histochemistry, flow cytometry, and histologic diagnosis for predicting increased cancer risk. , 1988, The American journal of pathology.

[37]  R. R. Smith,et al.  Prevalence and characteristics of Barrett esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction. , 1988, Human pathology.

[38]  B. Dahms,et al.  Barrett's esophagus in children: a consequence of chronic gastroesophageal reflux. , 1984, Gastroenterology.

[39]  T. Hennessy,et al.  Experimental columnar metaplasia in the canine oesophagus , 1988, The British journal of surgery.

[40]  Premalignant conditions of the gastrointestinal tract , 1991 .

[41]  C. Pope,et al.  Regression of columnar esophageal (Barrett's) epithelium after anti-reflux surgery. , 1980, The New England journal of medicine.

[42]  R. Sampliner,et al.  Ornithine decarboxylase assay in human colorectal mucosa. Methodologic issues of importance to quality control , 1992, International journal of cancer.

[43]  F. Ellis,et al.  Effect of antireflux operation on Barrett's mucosa. , 1990, The Annals of thoracic surgery.

[44]  J. Fraumeni,et al.  Rising incidence of adenocarcinoma of the esophagus and gastric cardia. , 1991, JAMA.

[45]  G Van Belle,et al.  Observer variation in the diagnosis of dysplasia in Barrett's esophagus. , 1988, Human pathology.

[46]  P. D. James,et al.  Value of DNA image cytometry in the prediction of malignant change in Barrett's oesophagus. , 1989, Gut.